News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
01
2025
-
12
Smart Chain Deepens Its Roots, Embracing All-Domain Innovation | Linuo Pharmaceutical Debuts at the 7th Ecological Innovation Conference for Listed Pharmaceutical and Healthcare Companies
Classification：
行业新闻
Corporate News
11 On the 23rd, the 7th Ecological Innovation Conference for Listed Pharmaceutical and Healthcare Companies was grandly held in Lishui, Zhejiang Province. Shandong Linuo Pharmaceutical Co., Ltd. (hereinafter referred to as “Linuo Pharmaceutical”), a benchmark enterprise for growth-oriented companies in the pharmaceutical industry, was invited to attend the conference. Chairman Li Hongfu delivered a keynote speech, providing an in-depth interpretation of the company’s development strategy—“Deepening Intelligent Chain Integration and Embracing New Horizons Across All Domains”—and comprehensively showcasing the company’s groundbreaking achievements in areas such as intelligent manufacturing, product innovation, and industrial collaboration, thereby injecting strong momentum into the high-quality development of the industry.
This conference, centered on the theme of “Ecological Innovation,” brought together leaders, experts, industry peers, and representatives from investment institutions in the pharmaceutical and healthcare sectors to jointly explore development opportunities and collaborative pathways amid the backdrop of industrial transformation. Lishui’s superior business environment and vibrant innovation ecosystem have provided an excellent platform for this industry event—a venue for the exchange of ideas and the alignment of resources.
In his speech, Chairman Li Hongfu pointed out that the pharmaceutical industry is currently undergoing a period of transformation and restructuring. The nation’s emphasis on technological innovation and new-quality productivity is providing clear direction for enterprise development. Linuo Pharmaceutical has always taken “innovation” as its core driving force, integrating it into every aspect of its ecosystem—including quality management, industrial chain collaboration, and intelligent manufacturing—to build competitiveness through systematic upgrades.
In terms of corporate strategic planning, Chairman Li Hongfu elaborated in detail on the practical achievements of Linuo Pharmaceutical’s “Four Major Founding Years” strategy—guided by four key initiatives: AI-powered full-scenario applications, internet-based thinking, data management, and investment & financing. Under this strategy, the company has comprehensively advanced its digital and intelligent transformation, establishing two domestically first-class, internationally benchmarked smart manufacturing bases: the Shanghe API base and the Jinan injectables base. Among these, the Shanghe base serves as a “stabilizing cornerstone,” ensuring independent supply of raw materials, while the Jinan base, centered around a computing power hub, connects to the Beijing R&D center, the Hainan GSP company, and other regional business nodes across China, creating an interconnected and collaboratively efficient industrial layout that has achieved dual breakthroughs in energy conservation, cost reduction, and quality enhancement.
In terms of product portfolio development, Linuo Pharmaceutical has achieved a transformative upgrade—from a focus solely on oral solid dosage forms to comprehensive coverage across multiple dosage forms, including injections, oral solutions, drops, topical applications, pastes, and sprays. Its business areas now span several core therapeutic segments, such as chronic disease management and anti-inflammatory and antibacterial treatments. Leveraging the synergistic advantages of “integrated raw material and formulation production” and “integrated excipient and formulation development,” the company has established a lineup of iconic products, including isosorbide mononitrate tablets and calcium dobesilate capsules, while also introducing several blockbuster new products, such as intravenous esaxolone sulfate and ferrous protein succinate oral solution.
Capital empowerment and open cooperation are key pillars supporting Linuo Pharmaceutical’s “All-Domain Innovation” strategy. As a publicly listed company, the firm leverages its capital strengths as a “precise navigation system” to map out short-, medium-, and long-term product development strategies. Through strategic equity investments in Beijing Nuokangda and the acquisition of Hainan Linheng Pharmaceutical, among other initiatives, the company has seamlessly integrated the entire industry chain—from R&D to services—achieving complementary advantages between R&D expertise and production and operational capabilities, thereby realizing a symbiotic effect where “1+1>2.”
At the conference, Chairman Li Hongfu emphasized in an interview with People's Daily Online: “Although walking alone may be fast, traveling together ensures greater longevity. Listed companies should play the role of a bridge and link, coordinating resources from industry, academia, research, and application to jointly create a healthy and open new industrial ecosystem.”
With more than two decades of deep industry expertise, Linuo Pharmaceutical has consistently embedded “long-termism, product-centricity, and altruism” into its very core, steadfastly upholding its mission of “caring for life and health, and safeguarding a better life.” At the conference, the company’s array of innovative products and strategic achievements drew widespread attention. Its quality management philosophy—“pursuing zero defects”—its unwavering long-term commitment to addressing chronic diseases, and its transformation from a “production supplier” to a “collaborative partner in the smart health ecosystem” all earned high recognition from industry peers.
Looking ahead, Linuo Pharmaceutical will continue to deepen its “intelligent chain cultivation,” accelerating the intelligent transformation of production lines and upgrading its digital quality management system to solidify its competitive advantages in cost and quality. At the same time, guided by the principle of “all-round innovation,” the company will enhance its market share of key products through participation in industry events, innovation in marketing models, and deepening channel partnerships. Leveraging industrial synergy, Linuo Pharmaceutical will also incubate new growth drivers. As Chairman Li Hongfu put it, Linuo Pharmaceutical will build on smart manufacturing as its foundation, use its product portfolio as its spearhead, harness capital collaboration as its momentum, and anchor itself in brand culture as its soul. Together with industry partners, we will move forward hand in hand, making a vital contribution to the high-quality development of China’s pharmaceutical and healthcare industry and safeguarding the health and well-being of the people.
Related news
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China
